nts, additional time requirements for data analysis or a IND and later NDA, preparation, discussions with the FDA, an FDA request for additional pre-clinical or clinical data or unexpected safety or manufacturing issues; 24 ?? manufacturing costs, pricing or reimbursement issues, or other factors that make the product not economical; and ?? the proprietary rights of others and their competing prod